Literature DB >> 21815622

Lipopolyplex ternary delivery systems incorporating C14 glycerol-based lipids.

Laila Kudsiova1, Barbara Fridrich, Jimmy Ho, M Firouz Mohd Mustapa, Frederick Campbell, Katharina Welser, Melanie Keppler, Tony Ng, David J Barlow, Alethea B Tabor, Helen C Hailes, M Jayne Lawrence.   

Abstract

The structure, biophysical properties and biological behavior of lipopolyplex ternary gene delivery vectors incorporating novel C14 glycerol based lipids of varying alkyl chain geometry (containing cis, trans or alkyne double bonds) have been studied in the presence and absence of a bifunctional targeting peptide designed to both condense DNA and confer integrin-specific targeting. In vitro transfection studies in breast cancer MDA-MB-231 cells revealed that ternary formulations of lipid:peptide:DNA (LPD) complexes prepared using the aforementioned lipids possessed highly synergistic transfection activity up to 2500-fold higher than their respective lipid:DNA (LD) or peptide:DNA (PD) counterparts. Furthermore, the small structural differences in the lipid alkyl chain geometries also resulted in pronounced differences in transfection within each type of formulation, whereby the trans lipids showed best activity when formulated as LD complexes, whereas the cis lipids were superior in LPD formulations. Confocal fluorescence internalization studies using labeled components of the formulations showed both the lipid and the DNA of LD complexes to be trapped in endocytic compartments, whereas in the case of LPD complexes, the DNA was clearly released from the endosomal compartments and, together with the peptide, internalized within the cell nucleus. Physicochemical characterization of the formulations carried out by light and neutron scattering, zeta potential measurement, and negative staining electron microscopy detected major structural differences between LD and LPD complexes. Gel electrophoresis assays additionally showed differences between the individual lipids tested in each type of formulation. In conclusion, the superior transfection of the trans lipids in the LD complexes was thought to be attributed to superior DNA binding caused by a more closely matched charge distribution of the more rigid, trans lipids with the DNA. In the case of the LPD complexes, the DNA was thought to be predominantly condensed by the cationic portion of the peptide forming a central core surrounded by a lipid bilayer from which the targeting sequence partially protrudes. The more fluid, cis lipids were thought to confer better activity in this formulation due to allowing more of the targeting peptide sequence to protrude.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21815622     DOI: 10.1021/mp2001796

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  3 in total

1.  Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor.

Authors:  G Weitsman; N J Mitchell; R Evans; A Cheung; T L Kalber; R Bofinger; G O Fruhwirth; M Keppler; Z V F Wright; P R Barber; P Gordon; T de Koning; W Wulaningsih; K Sander; B Vojnovic; S Ameer-Beg; M Lythgoe; J N Arnold; E Årstad; F Festy; H C Hailes; A B Tabor; T Ng
Journal:  Oncogene       Date:  2017-02-06       Impact factor: 9.867

2.  Development of lipopolyplexes for gene delivery: A comparison of the effects of differing modes of targeting peptide display on the structure and transfection activities of lipopolyplexes.

Authors:  Robin Bofinger; May Zaw-Thin; Nicholas J Mitchell; P Stephen Patrick; Cassandra Stowe; Ana Gomez-Ramirez; Helen C Hailes; Tammy L Kalber; Alethea B Tabor
Journal:  J Pept Sci       Date:  2018-10-16       Impact factor: 1.905

3.  Trichain cationic lipids: the potential of their lipoplexes for gene delivery.

Authors:  Laila Kudsiova; Atefeh Mohammadi; M Firouz Mohd Mustapa; Frederick Campbell; Katharina Welser; Danielle Vlaho; Harriet Story; David J Barlow; Alethea B Tabor; Helen C Hailes; M Jayne Lawrence
Journal:  Biomater Sci       Date:  2018-12-18       Impact factor: 6.843

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.